Document ID: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-4_04-cv-05429/USCOURTS-cand-4_04-cv-05429-56/pdf.json

Parties Involved:
Celtrix Pharmaceuticals, Inc.
Counter-claimant
Genentech, Inc.
Counter-defendant
Insmed Incorporated
Counter-claimant
Insmed Therapeutic Proteins
Defendant
Tercica, Inc.
Counter-defendant

Document Text:

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

Stipulation of Additional Facts and [Proposed] Order 

Case No. C-04-5429-CW (EMC) 

FOLEY & LARDNER LLP 

ATTORNEYS AT LAW 

1530 PAGE MILL ROAD 

PALO ALTO, CA 94304 

TELEPHONE: (650) 251-1114 

FAX: (650) 856-3710 

DAVID B. MOYER, BAR NO. 197739 

dmoyer@foley.com 

FOLEY & LARDNER LLP 

ATTORNEYS AT LAW 

3000 K ST., N.W. 

WASHINGTON, DC 20007 

TELEPHONE: 202.672.5300 

FAX: 202.672.5399 

LARRY L. SHATZER, PRO HAC VICE 

lshatzer@foley.com 

ANTHONY H. SON, BAR NO. 190478 

ason@foley.com 

GEORGE C. BEST, PRO HAC VICE 

gbest@foley.com 

FOLEY & LARDNER LLP 

ATTORNEYS AT LAW 

11250 EL CAMINO REAL, SUITE 200 

SAN DIEGO, CA 92130 

TELEPHONE: (858) 847-6700 

FAX: (858) 792-6773 

DOUGLAS H. CARSTEN, BAR NO. 198467 

dcarsten@foley.com 

HOWREY LLP 

525 MARKET STREET, SUITE 3600 

SAN FRANCISCO, CA 94105 

TELEPHONE: (415) 848-4900 

FAX: (415) 848-4999 

HENRY BUNSOW, BAR NO. 60707 

bunsowh@howrey.com 

DAVID BILSKER, BAR NO. 152383 

bilskerd@howrey.com 

RICK CHANG, BAR NO. 209515 

changr@howrey.com 

Attorneys for Defendants 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

OAKLAND DIVISION 

GENENTECH, INC., a Delaware Corporation, 

TERCICA, INC., a Delaware Corporation 

 Plaintiffs, 

 v. 

INSMED INCORPORATED, a Virginia 

Corporation, CELTRIX 

PHARMACEUTICALS, INC., a Delaware 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

Case No. C-04-5429 CW (EMC) 

NOTICE OF ADDITIONAL 

STIPULATED FACTS AND 

ORDER 

Case 4:04-cv-05429-CW Document 965 Filed 11/22/06 Page 1 of 3
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

 

 2 Stipulation of Additional Facts and [Proposed] Order 

Case No. C-04-5429-CW (EMC)

Corporation, and INSMED THERAPEUTIC 

PROTEINS, INC., a Colorado Corporation 

 Defendants. 

AND RELATED COUNTERCLAIMS 

) 

) 

) 

) 

) 

) 

Plaintiffs Genentech, Inc. (“Genentech”) and Tercica, Inc. (“Tercica”) (collectively 

Plaintiffs”) and Defendants Insmed Incorporated, Celtrix Pharmaceuticals, Inc., and Insmed 

Therapeutic Proteins (collectively “Defendants”) hereby submit the following Stipulated Facts. 

1. Insmed has a master cell bank that contains E. coli that Insmed uses to produce 

IGFBP-3. 

2. The cells in Insmed’s master cell bank have plasmids comprised of DNA used to 

express the IGFBP-3 protein. The DNA sequence Insmed uses to express the IGFBP-3 protein 

contained in the commercial preparation of iPLEX is set forth in PX-310 at p. 40 of 111. (INSM 

0686252). This DNA sequence was originally made at Celtrix in 1994. 

3. Mr. Kelley, Insmed’s Head of Intellectual Property, directed an Insmed employee 

to send a package containing samples from Insmed’s master cell bank to Dr. Parsley. 

4. Dr. Parsley received these samples from Insmed’s master cell bank from Insmed 

in January 2006. 

5. Mr. Glenn Kelley of Insmed further provided Mr. Parsley with sequencing reports 

for its master cell bank. 

6. OriGene is an independent company that supplies plasmids containing various 

genes to the biotechnology industry. 

7. Mr. Kelley purchased Origene plasmid 119779. 

8. Origene plasmid 119779 includes the DNA sequence from Figure 3 of the ’287 

patent. 

9. Mr. Kelley also purchased Origene plasmid 119777. 

10. Origene plasmid 119777 contains DNA encoding IGFBP-1. 

11. IGFBP-1 is referred to as BP28 in the ’287 patent. 

12. Mr. Kelley directed an Insmed employee to send Origene plasmid 119779 and 

Case 4:04-cv-05429-CW Document 965 Filed 11/22/06 Page 2 of 3
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

 

 3 Stipulation of Additional Facts and [Proposed] Order 

Case No. C-04-5429-CW (EMC)

Origene plasmid 119777 to Dr. Parsley. 

13. Dr. Parsley received Origene plasmid 119779 and Origene plasmid 119777 from 

Insmed. 

 The aforementioned facts establishing the chain of custody of the tested materials are 

HEREBY STIPULATED, by and between the parties hereto, through their respective counsel. 

 

Dated: November 19, 2006 McDERMOTT WILL & EMERY LLP 

 By:_________/s/__________________

 WILLIAM G. GAEDE III 

 Attorney for Plaintiff 

 TERCICA, INC. 

Dated: November 19, 2006 HELLER EHRMAN WHITE & MCAULIFFE LLP 

 By:___ /s/ 

 M. PATRICIA THAYER 

 Attorney for Plaintiff 

 GENENTECH, INC. 

Dated: November 19, 2006 By:______/s/________________________

 Rick Chang 

 Attorney for Defendants 

 INSMED, INC. AND CELTRIX 

 PHARMACEUTICALS, INC. 

ORDER 

 Concurrence in the filing of this document has been obtained from the signatories above. 

 PURSUANT TO STIPULATION, IT IS SO ORDERED 

Dated: __11/22/06_______________ ___________________________

 Hon. Claudia Wilken 

 United States District Judge 

Case 4:04-cv-05429-CW Document 965 Filed 11/22/06 Page 3 of 3